Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AVB-S6-500 + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AVB-S6-500||AVBS6500|AV S6 500||AVB-S6-500 is a fusion protein comprised of human IgG1 linked to the extracellular domain of Axl, which binds to growth arrest-specific protein 6 (GAS6), potentially resulting in decreased downstream signaling and reduced tumor growth (PMID: 32148495, PMID: 31599479).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04019288||Phase Ib/II||AVB-S6-500 + Durvalumab||AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Recruiting||USA||0|